Autopsy report · NCT03782818

Olaparib for PAH: a Multicenter Clinical Trial

“The recruitment was stopped on October 31st 2024 due to limited recruitment within the last year, as well as the end of funding (Spring 2025).”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months before it started.
• Ran for about 4 years 11 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Laval University

Sponsor type

University, hospital or other

Conditions

Pulmonary Arterial Hypertension

Interventions

Olaparib

Participants

17

Sites

3

Countries

Canada

Trials that died the same way

• Understanding Hemophilia A and B Drug Dosage Administration Patterns
  “Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. See details in Description section.” (76% match in meaning)
• High-intensity Exercise After Acute Cardiac Event (HITCARE)
  “Recruitment was stopped due to lack of funding.” (72% match in meaning)
• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  “The recruitment was halted for strategic reasons” (71% match in meaning)
• Digital Prevention of Asthma
  “The recruitment stopped due insufficient funding.” (71% match in meaning)
• Mesenchymal Stem Cell Transplantation in MS
  “Ended the recruitment in June 2012 for low enrollement accrual” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.